Skip to Content

news

Home | news | Press Releases

Press Releases

Dingell, Moolenaar Introduce Legislation to Prevent Offshoring Biotech Industry to China

Washington, June 3, 2026

U.S. Representatives Debbie Dingell (D-MI-06) and John Moolenaar (R-MI-02), Chairman of the Select Committee on China, introduced the Biotech Investment National Security Act (BINSA). This legislation would ensure American investment in adversary biotechnology is subject to the review requirements of the Comprehensive Outbound Investment National Security (COINS) Act. This would apply to biotechnology, including pharmaceutical development, biologics manufacturing, and clinical research and development.

“Biotechnology will shape the future of medicine, agriculture, manufacturing, and national security. This legislation is important because it will ensure that American investment does not inadvertently support the development or expansion of biotechnology industries that could threaten our economic and national security interests. The United States must remain the global leader in innovation, and we cannot afford to be dependent on foreign competitors – like the People’s Republic of China – for critical pharmaceutical ingredients, drug development, and medical supply chains. Strengthening America’s biotechnology and pharmaceutical industries will help protect patients, create jobs, and safeguard our nation’s health and security,” said Congresswoman Dingell.

What the Bill Does

  • Amends the COINS Act of 2025 to add biotechnology — specifically pharmaceutical and biological product development — to the list of sectors subject to outbound investment screening. 

  • Makes U.S. pharmaceutical licensing deals, joint ventures, and equity investments with Chinese covered foreign persons subject to Treasury Department review. 

  • Explicitly covers licensing deals involving technology and intellectual property.

  • Directs Treasury to issue implementing regulations within one year, consulting HHS, DOD, and the Director of National Intelligence. 

  • Requires the Secretary of Defense to assess within 60 days whether U.S. capital flows into Chinese biotechnology negatively affect national security and military readiness. 

  • Explicitly excludes agricultural biotechnology, industrial fermentation, and basic academic research.

Bill text can be found HERE.
Back to top